Pfizer Inc. $PFE Shares Acquired by Prospera Financial Services Inc

Prospera Financial Services Inc lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 108.6% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 179,393 shares of the biopharmaceutical company’s stock after acquiring an additional 93,382 shares during the period. Prospera Financial Services Inc’s holdings in Pfizer were worth $4,349,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently modified their holdings of the company. GKV Capital Management Co. Inc. purchased a new position in Pfizer during the first quarter worth about $27,000. Curio Wealth LLC increased its holdings in shares of Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,098 shares during the last quarter. Bayforest Capital Ltd acquired a new stake in shares of Pfizer during the 1st quarter worth approximately $28,000. Harbor Asset Planning Inc. purchased a new stake in shares of Pfizer during the 2nd quarter valued at approximately $29,000. Finally, WPG Advisers LLC acquired a new position in Pfizer in the first quarter valued at approximately $35,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Morgan Stanley decreased their target price on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Friday, October 10th. Bank of America increased their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. Finally, Sanford C. Bernstein reissued a “market perform” rating and issued a $30.00 price target on shares of Pfizer in a research note on Friday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $28.18.

Pfizer Trading Down 1.6%

NYSE PFE opened at $24.45 on Monday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The firm has a market cap of $138.99 billion, a price-to-earnings ratio of 13.00, a PEG ratio of 0.81 and a beta of 0.54. The firm has a 50 day simple moving average of $24.74 and a 200-day simple moving average of $24.38. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.69.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.08. The firm had revenue of $16.65 billion for the quarter, compared to the consensus estimate of $16.94 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is presently 100.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.